inThought Research provides analytical, forecasting, and competitive intelligence services that support strategic and tactical decisions of life science and financial firms.

We offer sophisticated integrated intelligence for decision support using a variety of data points, both primary and secondary, combined with our analysis and insight. Our methodology allows clients to triangulate actionable intelligence about their market and adjust strategy accordingly.

All of our subject matter experts are in-house.

inThought is an employee owned business.

Our Team

After completing his training in immunology and biochemistry, Dr. Weintraub began work as a financial analyst in 2000. Collaborating with Dr. Henderson, Dr. Weintraub co-founded BiotechTracker, an online tool for investors. In 2004, he became a licensed security analyst with Hibernia Southcoast Capital covering the biotechnology sector, and later performed the same role at Variant Research. In 2006, Dr. Weintraub joined Dr. Henderson and Dr. Zuckerman at Reuters Insight, providing analysis of drug development and trends in medicine to professional investors. Dr. Weintraub’s team moved to inThought in January 2009.  Through a divestiture by Wolters Kluwer, inThought and Source Healthcare Analytics became part of Symphony Health Solutions, a healthcare information company. inThought Research LLC formed a stand-alone company in May 2014.

Prior to 2000, Dr. Weintraub was senior scientific editor for the biology research journals Cell and Molecular Cell. Dr. Weintraub performed biochemistry and immunology research at Stanford University and at the John Curtin School of Medical Research in Canberra, Australia. He earned his doctorate in Biology from the University of California, San Diego, and a Bachelor of Science in Life Science from the Massachusetts Institute of Technology.

Mr. Martin has over fourteen years of experience in healthcare industry consulting, finance, and healthcare policy.  He previously served in health policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer for the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations. Mr. Martin was the Vice President of Research at Lese Investments LLC, a healthcare focused investment company, and co-portfolio manager at Cameron Capital.  He has also performed consulting in the healthcare industry at Biotech Tracker and McKinsey and Company. Mr. Martin has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science, with distinction, in Mechanical Engineering from Cornell University.
Dr. Engelsgjerd oversees coverage of the oncology sector, including marketed products, drug development, clinical trial design, emerging molecular targets, diagnostics, and cancer genomics/personalized medicine. He joined inThought from Coleman Research Group where he was Director of Healthcare Research.  Previously, Dr. Engelsgjerd spent five years analysing the biopharma industry for the investment community at Banc of America Securities, UBS Securities, and Reuters Insight. Before coming to Wall Street, he was at Research Corporation Technologies, an early-stage life sciences venture capital fund, where he vetted investment opportunities and helped to manage portfolio companies.  Dr. Engelsgjerd has also served as Director of Clinical Affairs at Veritas Medicine, an eHealth start-up company aimed at streamlining clinical trials recruitment. He completed a general surgery internship at the Barnes-Jewish Hospital (Washington University) and an anatomic pathology residency at the Brigham and Women’s Hospital.  Dr. Engelsgjerd earned his medical degree at the University of California, San Francisco, where he received the Dean’s Research Award. He graduated summa cum laude from the University of Arizona with a Bachelor of Science with Honors in Molecular & Cellular Biology.
Ms. Hoggatt covers the medical technology sector and some infectious disease and CNS indications. Ms. Hoggatt comes from Noble Financial where she was the Senior Medical Technology analyst.  Prior to Noble, Ms. Hoggatt helped start the independent research firm, Variant Research with Dr. Weintraub and Dr. Henderson.   Before Variant she worked at Hibernia Southcoast Capital, where she was also a Medical Technology Analyst and a Vice President of Equity Research.  Ms. Hoggatt began in the investment industry as an associate equity analyst at Morgan Keegan & Company covering medical devices and earned the title Associate Vice President of Equity Research.  Her professional career has been focused on the healthcare sector and has included in-depth coverage of over thirty different companies in the Medical Technology and Medical Device industries, allowing her to share a wealth of knowledge and insight with our clients. Ms. Hoggatt received her Bachelors of Business Administration and Master of Accountancy from Millsaps College in Jackson, Mississippi.
Ms. Crofskey has over 12 years of experience in medical writing, account management and pharmaceutical industry consulting. She provides coverage for the immunology and neurology sectors, including everything from emerging targets and drug development to market analysis and customized business intelligence. Prior to joining inThought, Ms. Crofskey worked as a medical writer for Wolters Kluwer in Auckland, New Zealand before moving to London to work as an Editorial Project Manager at Current Medicine Group, a Springer Healthcare company, and later, as an Editorial Project Manager at BioScience Communications. Ms. Crofskey returned to Wolters Kluwer in 2010 and subsequently joined the inThought team as a consultant in 2011. Ms. Crofskey earned her Bachelor of Science in Neuroscience and Pharmacology from the University of Otago in New Zealand.
Dr. Kennedy joined inThought in 2014 after completing a postdoctoral fellowship in human genetics at Albert Einstein College of Medicine. There, she investigated the genetic and molecular epidemiology of hyperhidrosis, as well as performed studies to validate the use of HPV DNA methylation as a diagnostic/predictive biomarker for risk of developing cervical cancer. Previously, Dr. Kennedy obtained her PhD in Genetics and Development at Columbia University where she studied the regulation of cell migration using C. elegans. While at Columbia, Dr. Kennedy also held a fellowship with the Columbia technology transfer office where she was responsible for assessing IP assets across diverse biomedical disciplines within the university. Dr. Kennedy earned her Bachelor of Science from Cornell University.
Dr. Henderson-MacLennan is an internal medicine specialist and clinical geneticist practicing in Southern California and serving domestic and international clientele. Dr. Henderson-MacLennan, an applied health services research expert, has consulted for academia and industry on the biotechnology industry and has authored medical literature and healthcare economics literature. Originally called on by Fidelity to provide expert analysis of drugs, Dr. Henderson-MacLennan has collaborated with Dr. Weintraub to developed models for over 300 drugs that are either on the market or in clinical development. Prior to joining inThought in January 2009, Dr. Henderson-MacLennan and Dr. Weintraub performed investment research at BiotechTracker, Hibernia Southcoast Capital, Variant Research, and Reuters Insight. Dr. Henderson-MacLennan earned a medical degree from Cornell University and a Bachelor of Arts in Linguistics from Northwestern University.
Dr. Zuckerman earned his medical degree from Howard University College of Medicine in Washington, D.C. and a Bachelor of Arts from the University of Michigan in Ann Arbor, Michigan. After completing medical school, Dr. Zuckerman did his residency in Obstetrics and Gynecology in Brooklyn, New York.  Dr. Zuckerman identifies, recruits, and develops consulting relationships with medical leaders and experts to provide evidence based insights into healthcare research. Dr. Zuckerman has worked with Dr. Henderson and Dr. Weintraub since 2006.
After obtaining his PhD degree in organic chemistry at Cornell University, Dr. Yee conducted enzymological research as a Stipendiat at the Max Planck Institute for Experimental Medicine in Göttingen, Germany and as a research associate at Harvard University. He was Director of Research and Development for a biopharmaceutical company before joining the Genesis Group as Senior Technology Analyst. In the latter position, he provided strategic analysis and forecasting of technology and market trends within the pharmaceutical and biotechnology sectors, projected future technology trends for various disease states based on market survey analysis, and assessed the competitive impact of technologies and programs in development against currently marketed agents. In 2003 the Genesis Group was acquired by Wolters Kluwer, where Dr. Yee continued to use his scientific background in providing customized business intelligence to the pharmaceutical industry.
Dr. Higashimura joined inThought in January 2012. Her areas of focus include systemic lupus, inflammatory bowel disease, hemophilia, multiple sclerosis and type-2 diabetes. Prior to joining inThought, Dr. Higashimura practiced veterinary medicine for over 10 years, including 5 years as a Chief of Staff of a veterinary hospital. She has worked at the Bronx and National Zoos and done research on hemolytic anemia in rhinoceroses. Dr. Higashimura earned her Doctor of Veterinary Medicine from Tufts University and her Bachelor of Science from Cornell University.
Ms. McCarthy joined inThought in 2014.  Her background is in asset management concentrating on security and manager research and due diligence.  She spent seven years working as an Analyst covering all asset classes as well as alternative strategies within investments for Bank of New York and Park Avenue Securities.  Ms. McCarthy’s experience also includes quantitative strategies and equity research while working for Aberdeen Asset Management and a hedge fund.  She earned her Bachelor of Management from A.B Freeman School of Business at Tulane University and holds Series 65 and 7 certifications.
Ms. Green joined inThought Research in 2015.  She holds a Master of Science in Health Communication, with a concentration in Applied Communication Research, and a Master of Public Health from Boston University.  Prior to joining inThought she founded Research Acadiana, LLC, a market research consultancy helping clients meet their objectives through customized data collection and analysis.  Ms. Green previously worked as a Sr. Research Analyst at Eidetics in Boston (now Quintiles Consulting) where she participated in all phases of primary market research for pharmaceutical and biotechnology clients.  While completing graduate school, she was a Research Associate at Mapi Values (now Adelphi Values) where she conducted patient-reported outcomes research, identified clinical endpoints, and developed outcomes assessment instruments for use in clinical trials.  She received her BA in Sociology and Psychology from Millsaps College in Jackson, MS.
Prior to joining inThought, Dr. Weyerbacher was a scientific consultant to biotechnology companies, providing scientific and regulatory analysis of compounds and distinct therapeutic combinations. She has previously worked as a Senior Scientist in Research and Development at L’Oreal. In this role, she managed the clinical testing program of multiple consumer products and supported cross-functional teams with scientific leadership and expertise to facilitate blockbuster product launches. Dr. Weyerbacher graduated from Skidmore College with a Bachelor’s degree in Biology-Chemistry before receiving a PhD in Pharmacology from Weill Cornell Medical College. Her dissertation research focused on the identification of critical pain signaling proteins, cytokines and immune/central nervous system interactions as relevant pharmacological targets for clinical pain control. In between college and graduate school, Dr. Weyerbacher was a Research Study Assistant at Memorial Sloan Kettering Cancer Center. In this role, she managed an active clinical trial program, defining and monitoring project scope, timelines and deliverables from project initiation to close-out. She has presented her research in pharmacology, neuroscience and oncology at several scientific conferences. Dr. Weyerbacher is the immediate past President of the MetroNY Chapter of the Association for Women in Science (AWIS).
Dr. Basu joined inThought in 2015, after completing her post-doctoral studies in Immunology at Memorial Sloan-Kettering Cancer Center, where she studied mechanisms potentiating cytotoxic T cells. While at MSKCC, she also worked as a Life Science Analyst for a boutique consulting firm, providing due diligence on diverse therapeutic areas to hedge funds and mutual funds. In addition to research, Dr. Basu has regularly been involved in several public health and science education projects in the New York City area. She earned her PhD in Cell Biology from Columbia University in New York and a B.Sc. in Biology from McGill University in Montréal.

Ms. Cameron joined inThought in 2016, where she primarily provides coverage for the immunology, oncology and neurology sectors. Ms. Cameron transferred to inThought from Springer Healthcare, where she served as a Medical Writer for the Adis Insight suite of products. Her more than 20-year career as a medical writer and managing editor has included coverage of all therapeutic areas. Prior to Adis Insight, Ms. Cameron worked at the University of Auckland in New Zealand, initially at the Post-Graduate School of Obstetrics and Gynecology, and later for the Department of Physiology. During her time with the University of Auckland, Ms. Cameron took part in fertility, cardiovascular, audiology and respiratory research projects.

Mr. Tapley is inThought’s Information Technology Director and the lead architect and developer for the inVision system – our online healthcare knowledge management software. Prior to joining inThought he spent over 15 years leading companies that worked with clients in healthcare, finance, and education. Mr. Tapley became involved with inThought after it launched as a stand-alone company in May 2014 to assist Dr. Weintraub with inVision. He is also our in-house technology expert and leads our technology support team for client services. Eric Tapley received a BS in Social and Environmental Policy Analysis with System Dynamics from Worcester Polytechnic Institute (WPI) and holds certificates from Boston University in small business entrepreneurship.
Prior to joining the inThought team in 2017, Dr. Weinberg completed a program in data science and machine learning, working as a data science consultant in New York. Dr. Weinberg holds a PhD from Columbia University, where he studied the genetic regulation of neural development, and a BA from Bard College. While at Columbia, he also worked as a fellow in the technology transfer office, evaluating and assessing the commercial potential of a broad range of natural and physical science technologies developed on campus.
Dr. Schaffner joined inThought in 2017 after earning his PhD in Biomedical Sciences at the Mount Sinai School of Medicine in New York, where he developed novel therapeutic strategies to target Parkinson’s Disease and other neurodegenerative disorders. While completing his dissertation, he worked as a venture intern at Celdara medical, where he conducted due diligence on academic innovations for partnership, development, and investment opportunities. Beyond the science, Dr. Schaffner has held various leadership roles as a student at Mount Sinai, and served as Co-founder and Co-chair of the Trainee Health and Wellness (THAW) Committee, which tackles systemic issues endangering the mental well-being of academic research trainees. He earned his Bachelor of Science in Biochemistry at the University of California, Los Angeles.